PTHS
Income statement / Annual
Last year (2025), Pelthos Therapeutics Inc.'s total revenue was $16.80 M,
and the percentage change from the previous year is not available.
In 2025, Pelthos Therapeutics Inc.'s net income was -$43.32 M.
See Pelthos Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$16.80 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$199.93 K |
| Cost of Revenue |
$6.27 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$10.52 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$199.93 K
|
| Gross Profit Ratio |
0.63
|
0
|
0
|
0
|
0
|
1
|
| Research and Development Expenses |
$1.23 M
|
$1.18 M
|
$2.58 M
|
$391.73 K
|
$209.05 K
|
$138.59 K
|
| General & Administrative Expenses |
$0.00
|
$6.39 M
|
$4.28 M
|
$1.93 M
|
$629.95 K
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$41.72 M
|
$6.39 M
|
$4.28 M
|
$1.93 M
|
$629.95 K
|
$1.42 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$42.95 M
|
$7.57 M
|
$6.86 M
|
$2.32 M
|
$839.00 K
|
$1.55 M
|
| Cost And Expenses |
$49.23 M
|
$7.57 M
|
$6.86 M
|
$2.32 M
|
$839.00 K
|
$1.55 M
|
| Interest Income |
$5.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$3.01 M
|
$786.39 K
|
$518.51 K
|
$140.43 K
|
$253.00
|
$1.68 K
|
| Depreciation & Amortization |
$2.36 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
-$30.07 M |
-$7.17 M |
-$6.86 M |
-$2.32 M |
-$595.13 K |
-$658.91 K |
| EBITDA Ratio |
-1.79
|
0
|
0
|
0
|
0
|
-3.3
|
| Operating Income Ratio |
-1.93
|
0
|
0
|
0
|
0
|
-6.77
|
| Total Other Income/Expenses Net |
-$18.28 M
|
-$383.89 K
|
-$518.51 K
|
-$140.43 K
|
$243.61 K
|
$693.28 K
|
| Income Before Tax |
-$50.71 M
|
-$7.96 M
|
-$7.38 M
|
-$2.46 M
|
-$595.39 K
|
-$660.58 K
|
| Income Before Tax Ratio |
-3.02
|
0
|
0
|
0
|
0
|
-3.3
|
| Income Tax Expense |
-$7.39 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$43.32 M
|
-$7.96 M
|
-$7.38 M
|
-$2.46 M
|
-$595.39 K
|
-$660.58 K
|
| Net Income Ratio |
-2.58
|
0
|
0
|
0
|
0
|
-3.3
|
| EPS |
-23.04 |
-13.54 |
-12.8 |
-4.26 |
-1 |
-1.15 |
| EPS Diluted |
-23.04 |
-13.54 |
-12.8 |
-4.26 |
-1 |
-1.15 |
| Weighted Average Shares Out |
$1.88 M
|
$587.62 K
|
$576.75 K
|
$576.75 K
|
$576.75 K
|
$576.75 K
|
| Weighted Average Shares Out Diluted |
$1.88 M
|
$587.62 K
|
$576.75 K
|
$576.75 K
|
$576.75 K
|
$576.75 K
|
| Link |
|
|
|
|
|
|
